NCT01046851

A Study of Nopan Treatment of Acute Suicidality

Phase 3 Study of the Effects of Nopan as add-on Treatment to Antidepressants in Treating Depression and Suicidality

• Status: Unknown
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Prof. Yoram Yovell · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

Anecdotal evidence and several clinical studies found the mixed opioid agonist-antagonist Nopan to be an effective antidepressant with a rapid onset of action. It is therefore hypothesized that Nopan may be a novel and quick-acting treatment for acute suicidality. Depression, suicidality, and overall functioning will be assessed before, during and after a four-week Nopan/placebo trial. It is hypothesized that subjects who receive the active drug will show rapid improvements in objective and subjective measures of these variables.

Conditions

• Suicidality

Interventions

Type	Name	Description
DRUG	Nopan	Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
DRUG	Placebo	Placebo in a manner similar to the active comparator

Timeline

• Start date: 2008-09-01
• Primary completion: 2011-12-01
• Completion: 2011-12-01
• First posted: 2010-01-12
• Last updated: 2012-01-04

Locations

3 sites across 1 country: Israel